食管癌放疗中氨溴索预防放射性肺炎的临床研究  

Clinical study of the prevention of ambroxol on radiation-induced pneumonitis in radiotherapy for esophagus cancer

作　　者：冯艳[1] 薛良军[1] 

机构地区：[1]皖南医学院附属弋矶山医院放疗科,安徽芜湖241001

出　　处：《临床肺科杂志》2011年第12期1908-1909,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的对氨溴索在食管癌放射治疗时减少急、慢性放射性肺炎的发生率进行评价。方法 80例食管癌患者接受常规放疗,随机分为单纯放疗组(RT)40例和放疗加氨溴索组(RT+A)40例。氨溴索用法:从放疗首日开始,氨溴索90 mg ivdbid,直至放疗结束。结果 80例患者治疗后3个月放射性肺炎≥2级者RT组占10/38(26.32%),RT+A组为3/39(7.69%),两组比较有差异(P<0.05)。6个月和12个月时,肺纤维化的发生率RT组分别为8/38(21.05%)、11/38(28.95%),RT+A组分别为3/39(7.69%)、4/39(10.26%),两组比较有差异(P<0.05)。结论氨溴索在食管癌放射治疗时能够降低急、慢放射性肺炎的发生率。Objective The clinically investigate whether daily pretreatment with ambroxol（A） could reduce the incidence of acute and chronical radiation-induced pneumonitis in radiotherapy for esophagus cancer.Methods Patients（n=80）with 6MV X-ray radiotherapy（RT） received a daily fraction of 200cGY/5days/week in an approximately total dose of 6400cGY with or without ambroxol 90mg ivd bid,starting on the first day of radiotherapy.Acute and chronical radiation-induced pneumonitis were graded from 0 to 4 according to RTOG.Results The patients＇ data（n=80） were evaluated.One month post-RT for the incidence of pneunonitis was 26.32% of patients in the RT group and 7.69% in the RT＋A group experiencing≥Grade 2 pneumonitis.There was a significant difference between the two groups.At the end of the 6th and 12th months,fibrosis was present in 21.05% and 28.95% receiving RT vs 7.69% and 10.26% receiving RT＋A.There was a significant difference between them.Conclusions Ambroxol can reduce the incidence of pneumonitis and fibrosis in radiotherapy for esophagus cancer.

关 键 词：氨溴索 食管癌 放射治疗 放射性肺炎 

分 类 号：R735.1[医药卫生—肿瘤] R818.7[医药卫生—临床医学]